Difference between revisions of "Paclitaxel, nanoparticle albumin-bound (Abraxane)"
Jump to navigation
Jump to search
m (also known as) |
(updated content) |
||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
| − | Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization. Paclitaxel interferes with the normal dynamic reorganization of microtubules that is necessary for regular interphase/mitosis processes. It also leads to creation of abnormal bundles of microtubules. The nanoparticle albumin bound characteristic of Abraxane eliminates the need for it to be dissolved in Cremophor EL (polyoxyethylated castor oil) like [[Paclitaxel (Taxol)]] and the risk of hypersensitivity infusion reactions related to Cremophor.<ref name="insert">[http://www.abraxane.com/docs/Abraxane_PrescribingInformation.pdf Paclitaxel, albumin-bound (Abraxane) package insert]</ref><ref>[ | + | Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization. Paclitaxel interferes with the normal dynamic reorganization of microtubules that is necessary for regular interphase/mitosis processes. It also leads to creation of abnormal bundles of microtubules. The nanoparticle albumin bound characteristic of Abraxane eliminates the need for it to be dissolved in Cremophor EL (polyoxyethylated castor oil) like [[Paclitaxel (Taxol)]] and the risk of hypersensitivity infusion reactions related to Cremophor.<ref name="insert">[http://www.abraxane.com/docs/Abraxane_PrescribingInformation.pdf Paclitaxel, nanoparticle albumin-bound (Abraxane) package insert]</ref><ref>[[Media:Paclitaxelalbuminbound.pdf|Paclitaxel, nanoparticle albumin-bound (Abraxane) package insert (locally hosted backup)]]</ref><ref>[http://www.abraxane.com/ Abraxane manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: [[irritant]] | <br>Extravasation: [[irritant]] | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Breast cancer]] | ||
| + | *[[Melanoma]] | ||
| + | *[[Non-small cell lung cancer]] | ||
| + | *[[Ovarian cancer]] | ||
| + | *[[Pancreatic cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://www.abraxane.com/docs/Abraxane_PrescribingInformation.pdf#page= | + | *[http://www.abraxane.com/docs/Abraxane_PrescribingInformation.pdf#page=8 Paclitaxel, nanoparticle albumin-bound (Abraxane) package insert PDF page 8]<ref name="insert"></ref> |
| + | *[http://www.chemocare.com/chemotherapy/drug-info/Paclitaxel-Proteinbound.aspx Paclitaxel, nanoparticle albumin-bound (Abraxane) patient drug information (Chemocare)]<ref>[http://www.chemocare.com/chemotherapy/drug-info/Paclitaxel-Proteinbound.aspx Paclitaxel, nanoparticle albumin-bound (Abraxane) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/paclitaxel-nanoparticle-albumin-bound-patient-drug-information Paclitaxel, nanoparticle albumin-bound (Abraxane) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/paclitaxel-nanoparticle-albumin-bound-patient-drug-information Paclitaxel, nanoparticle albumin-bound (Abraxane) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/paclitaxel-nanoparticle-albumin-bound-patient-drug-information Paclitaxel, nanoparticle albumin-bound (Abraxane) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/paclitaxel-nanoparticle-albumin-bound-patient-drug-information Paclitaxel, nanoparticle albumin-bound (Abraxane) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *1/7/2005: FDA approved for "metastatic Breast Cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated."<ref name="insert"></ref> | ||
| + | *10/11/2012: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm323668.htm FDA approved] for "locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy."<ref name="insert"></ref> | ||
| + | |||
| + | ==Also known as== | ||
| + | ABI-007, ab-pac, ab-paclitaxel, albumin-bound paclitaxel, nab-paclitaxel, Paclitaxel Protein-bound, paclitaxel protein-bound particles for injectable suspension (albumin-bound). | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Irritant chemotherapy]] | ||
| + | [[Category:Microtubule inhibitors]] | ||
| + | [[Category:Taxanes]] | ||
| + | [[Category:Breast cancer medications]] | ||
| + | [[Category:Melanoma medications]] | ||
| + | [[Category:Ovarian cancer medications]] | ||
| + | [[Category:Pancreatic cancer medications]] | ||
Revision as of 15:32, 14 June 2013
General information
Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization. Paclitaxel interferes with the normal dynamic reorganization of microtubules that is necessary for regular interphase/mitosis processes. It also leads to creation of abnormal bundles of microtubules. The nanoparticle albumin bound characteristic of Abraxane eliminates the need for it to be dissolved in Cremophor EL (polyoxyethylated castor oil) like Paclitaxel (Taxol) and the risk of hypersensitivity infusion reactions related to Cremophor.[1][2][3]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Paclitaxel, nanoparticle albumin-bound (Abraxane) package insert PDF page 8[1]
- Paclitaxel, nanoparticle albumin-bound (Abraxane) patient drug information (Chemocare)[4]
- Paclitaxel, nanoparticle albumin-bound (Abraxane) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 1/7/2005: FDA approved for "metastatic Breast Cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated."[1]
- 10/11/2012: FDA approved for "locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy."[1]
Also known as
ABI-007, ab-pac, ab-paclitaxel, albumin-bound paclitaxel, nab-paclitaxel, Paclitaxel Protein-bound, paclitaxel protein-bound particles for injectable suspension (albumin-bound).
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Paclitaxel, nanoparticle albumin-bound (Abraxane) package insert
- ↑ Paclitaxel, nanoparticle albumin-bound (Abraxane) package insert (locally hosted backup)
- ↑ Abraxane manufacturer's website
- ↑ Paclitaxel, nanoparticle albumin-bound (Abraxane) patient drug information (Chemocare)
- ↑ Paclitaxel, nanoparticle albumin-bound (Abraxane) patient drug information (UpToDate)